Loading…

Immunomodulating effects of the new anti-rheumatic drug tenidap on collagen-induced arthritis

We investigated the in vivo action of the newly developed anti-rheumatic agent tenidap, CP-66,248 (Pfizer Inc., New York), on arthritis in collagen-induced arthritic mice. The inhibitory effect of tenidap on the development of arthritis was statistically more significant than piroxicam. The serum an...

Full description

Saved in:
Bibliographic Details
Published in:International journal of immunopharmacology 1995-03, Vol.17 (3), p.213-219
Main Authors: Matsushita, Isao, Matsuno, Hiroaki, Kadowaki, Ken M., Okada, Chisako, Tsuji, Haruo
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We investigated the in vivo action of the newly developed anti-rheumatic agent tenidap, CP-66,248 (Pfizer Inc., New York), on arthritis in collagen-induced arthritic mice. The inhibitory effect of tenidap on the development of arthritis was statistically more significant than piroxicam. The serum anti-type II collagen antibody titer was markedly inhibited in the mice treated by tenidap. These results suggest that, unlike NSAIDs, tenidap inhibits the progress of collagen-induced arthritis through its immunomodulating effect.
ISSN:0192-0561
1879-3495
DOI:10.1016/0192-0561(95)00004-L